Butyrylcholinesterase (BuChE) activity is increasing in Alzheimer Disease (AD) process (Lane et al., 2006). BuChE wild type has stronger butyrylcholine esterase activity than BuChE K variant allele and this strong activity can affect AD brain negatively by choline depletion. Rivastigmine has unique dual action - acetylcholine esterase inhibition and butyrylcholine esterase inhibition. Therefore, rivastigmine can lower serum butyrylcholine esterase activity and delay functional decrease of Fluorodeoxyglucose positron emission tomography (FDG PET) images in AD patients with BuChE wild type allele by strong BuChE inhibition. It suggests that rivastigmine can affect brain function differently by BuChE genotype in AD. Therefore, we will try to find the different changes of serum butyrylcholine esterase activity by ELISA and functional and structural changes of brain between BuChE wild type and K-variant type by FDG PET and MRI pre and post images after 12 month use of rivastigmine. 1. Primary objective: 1. the mean changes of Standardized Uptake Values (SUVmean) in PET imaging 2. the mean changes of serum BuChE activity between BuChE wild type and K-variant type. 2. Secondary objectives: 1. the mean changes of cortical thickness in brain MRI 2. the cognitive changes in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) 3. the cognitive changes in Mini-Mental State Exam (MMSE) 4. the daily function changes by Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) 5. the behavioural changes by Caregiver-Administered Neuropsychiatric Inventory (NPI) 6. the disease severity changes by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) between BuChE wild type and K-variant type.
Age range
55 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
the mean changes of Standardized Uptake Values (SUVmean) in PET imaging
Timeframe: screening and 52weeks (2 times)
the mean changes of serum BuChE activity between BuChE wild type and K-variant type
Timeframe: screening and 52weeks (2 times)